JPWO2023156970A5 - - Google Patents
Info
- Publication number
- JPWO2023156970A5 JPWO2023156970A5 JP2024543311A JP2024543311A JPWO2023156970A5 JP WO2023156970 A5 JPWO2023156970 A5 JP WO2023156970A5 JP 2024543311 A JP2024543311 A JP 2024543311A JP 2024543311 A JP2024543311 A JP 2024543311A JP WO2023156970 A5 JPWO2023156970 A5 JP WO2023156970A5
- Authority
- JP
- Japan
- Prior art keywords
- amount
- subject
- therapeutically effective
- administration
- pharmaceutical composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263311536P | 2022-02-18 | 2022-02-18 | |
| US63/311,536 | 2022-02-18 | ||
| PCT/IB2023/051467 WO2023156970A1 (en) | 2022-02-18 | 2023-02-17 | Treatment of hypertriglyceridemia with 2-hydroxypropyl-beta-cyclodextrin |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2025508660A JP2025508660A (ja) | 2025-04-10 |
| JP2025508660A5 JP2025508660A5 (https=) | 2026-02-24 |
| JPWO2023156970A5 true JPWO2023156970A5 (https=) | 2026-02-24 |
Family
ID=85476260
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024543311A Pending JP2025508660A (ja) | 2022-02-18 | 2023-02-17 | ２－ヒドロキシプロピル－β－シクロデキストリンによる高トリグリセリド血症の治療 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20240398849A1 (https=) |
| EP (1) | EP4479064A1 (https=) |
| JP (1) | JP2025508660A (https=) |
| KR (1) | KR20240148426A (https=) |
| CN (1) | CN118715017A (https=) |
| AU (1) | AU2023222567A1 (https=) |
| CA (1) | CA3244447A1 (https=) |
| IL (1) | IL315046A (https=) |
| MX (1) | MX2024010110A (https=) |
| TW (1) | TW202342072A (https=) |
| WO (1) | WO2023156970A1 (https=) |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR0307518A (pt) * | 2002-02-01 | 2004-12-28 | Shimoda Biotech Pty Ltd | Composição farmacêutica |
| CN1745746A (zh) * | 2004-09-09 | 2006-03-15 | 天津药物研究院 | 冰片的羟丙基－β－环糊精包合物及其制剂和制备方法 |
| CN1961892A (zh) * | 2005-11-08 | 2007-05-16 | 天津药物研究院 | 降香羟丙基－β－环糊精包合物及其制剂和制备方法 |
| GB0710439D0 (en) * | 2007-05-31 | 2007-07-11 | Uni I Oslo | Oral dosage form |
| JP5847721B2 (ja) * | 2009-10-08 | 2016-01-27 | ソン、ホ、バイオメッド、カンパニー、リミテッドＳｏｎｇ Ｈｏ Ｂｉｏｍｅｄ Ｃｏ．， Ｌｔｄ | 高水溶性２−ヒドロキシプロピル−ベータシクロデキストリンを有効成分として含有する、肥満疾患の予防および治療用組成物 |
| FR3014694B1 (fr) * | 2013-12-13 | 2016-11-11 | Roquette Freres | Compositions a base de methyl-cyclodextrines pour le traitement et/ou la prevention de maladies par augmentation du taux de cholesterol-hdl |
-
2023
- 2023-02-17 CN CN202380022294.5A patent/CN118715017A/zh active Pending
- 2023-02-17 JP JP2024543311A patent/JP2025508660A/ja active Pending
- 2023-02-17 CA CA3244447A patent/CA3244447A1/en active Pending
- 2023-02-17 AU AU2023222567A patent/AU2023222567A1/en active Pending
- 2023-02-17 IL IL315046A patent/IL315046A/en unknown
- 2023-02-17 KR KR1020247030936A patent/KR20240148426A/ko active Pending
- 2023-02-17 MX MX2024010110A patent/MX2024010110A/es unknown
- 2023-02-17 WO PCT/IB2023/051467 patent/WO2023156970A1/en not_active Ceased
- 2023-02-17 EP EP23708901.6A patent/EP4479064A1/en active Pending
- 2023-02-18 TW TW112105977A patent/TW202342072A/zh unknown
-
2024
- 2024-08-12 US US18/801,161 patent/US20240398849A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Arbit | The physiological rationale for oral insulin administration | |
| JP6795571B2 (ja) | グリブリドおよび他の薬剤の静脈内投与方法 | |
| CN103480002A (zh) | 施用与人载脂蛋白 b互补的反义寡核苷酸 | |
| CN104159598A (zh) | 治疗糖尿病的方法和组合物 | |
| JP6440843B2 (ja) | 脂肪代謝の調節に供する医薬品の製造のための第一鉄アミノ酸キレートを含む組成物の使用 | |
| JP7639156B2 (ja) | チルゼパチド治療方法 | |
| ES2202449T3 (es) | Inhibidor de edema cerebral. | |
| Dimitriadis et al. | Effects of α-glucosidase inhibition on meal glucose tolerance and timing of insulin administration in patients with type I diabetes mellitus | |
| Fujita et al. | Haemodynamic effects of inhaled nitric oxide in acute myocardial infarction complicated by right heart failure under ECPELLA support: case report | |
| Suzuki et al. | Comparison of combined tofogliflozin and glargine, tofogliflozin added to insulin, and insulin dose-increase therapy in uncontrolled type 2 diabetes | |
| CN113599385B (zh) | 阿夫唑嗪在制备治疗糖尿病及其并发症药物中的应用 | |
| JPWO2023156970A5 (https=) | ||
| US20240261287A1 (en) | Methods of treating antipsychotic-induced weight gain with miricorilant | |
| BRPI0721741A2 (pt) | mÉtodo de tratamento de diabetes | |
| Ando et al. | Re‐elevation of serum amlodipine level after lipid emulsion therapy in an overdose case. | |
| Masi et al. | Acute amiodarone toxicity due to an administration error: could excipient be responsible? | |
| McCormick et al. | Treatment of type 2 diabetes mellitus: pharmacologic intervention | |
| WO2024042518A1 (en) | Glp-1 receptor antagonist and methods of use thereof | |
| JP7760169B2 (ja) | 腎機能改善用組成物 | |
| US20120283332A1 (en) | Transdermal delivery of metformin | |
| CN117298084A (zh) | 组蛋白乙酰基转移酶抑制剂在制备改善肥胖所致的非酒精性脂肪性肝病的药物中的应用 | |
| Montgomery et al. | Neuroleptic malignant syndrome in the intensive therapy unit | |
| Zeidan et al. | Transient glucose intolerance associated with the haemolytic-uraemic syndrome | |
| WO1999030698A1 (en) | A drug for treating diabetic nephrosis and delaying renal failure | |
| Gonzalez et al. | The poisoned patient |